Jordan’s Hikma Sails On Strong Winds From Injectables, But Generics Lag
This article was originally published in PharmAsia News
Executive Summary
A slower than expected remediation process with U.S. FDA for its Eatontown, New Jersey, plant has cast a shadow on Hikma’s generics business and may lead to a restructuring or even sale of the unit.